Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. COVID 19
  4. Back
  5. Board Wide
  6. Covid-19 Remdesivir for patients with COVID-19 (Adults and Adolescents 12 years and older) (1021)
Announcements and latest updates

test announcement

Covid-19 Remdesivir for patients with COVID-19 (Adults and Adolescents 12 years and older) (1021)

Remdesivir is an adenosine nucleotide prodrug that is metabolised intracellularly to form the pharmacologically active substrate remdesivir triphosphate. Remdesivir triphosphate inhibits SARS-CoV-2 RNA polymerase which perturbs viral replication.

Current evidence shows that remdesivir improves clinical outcomes in both hospitalised and non-hospitalised patients with COVID-19.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 12/06/2024

Next review date: 31/01/2027

Author(s): Samantha Carmichael, Beth White.

Version: 3

Author email(s): samantha.carmichael@ggc.scot.nhs.uk, beth.white@ggc.scot.nhs.uk.

Approved By: Covid-19 Tactical Group (Acute)

Reviewer name(s): Samantha Carmichael, Beth White.

Document Id: 1021